Ⓐ
PeptiBrief
First in human study· 2015

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist

Brame AL|Maguire JJ|Yang P|Dyson A|Torella R|Cheriyan J|Singer M|Glen RC|Wilkinson IB|Davenport AP

Hypertension

DOI
10.1161/hypertensionaha.114.05099
PubMed
25712721
Evidence level
moderate
Verification
verified

Summary

A synthetic biased apelin-receptor agonist was characterised preclinically and evaluated in a first-in-human vascular study.

Limitations

Early phase|Small sample|Short-term vascular endpoints|Synthetic agonist rather than native apelin-13

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.